Celularity Inc(CELU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 22 at 7:30 PM ET (Korea 9/23 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.58 | Insider Own | 44.28% | Shs Outstand | 28.8M | Perf Week | -4.84% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 16.1M | Perf Month | 47.49% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | - | Inst Own | 7.61% | Short Float | 11.77% | Perf Quarter | 68.62% |
| Income | -0.09B | P/S | 1.29 | EPS this Y | - | Inst Trans | 0.2% | Short Ratio | 0.49 | Perf Half Y | -2.48% |
| Sales | 0.03B | P/B | - | EPS next 5Y | - | ROA | -29.73% | Short Interest | 1.90M | Perf YTD | 6.31% |
| Book/sh | -1.32 | P/C | 5.54 | EPS past 3/5Y | - 49.85% | ROE | -6367.24% | 52W High | -53.73% ($2.55) | Perf Year | -44.34% |
| Cash/sh | 0.21 | P/FCF | - | Sales past 3/5Y | 13.88% 13.21% | ROIC | -446.63% | 52W Low | 110.68% ($0.56) | Perf 3Y | -48.7% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -35.2% | Gross Margin | -3.08% | Volatility(W/M) | 10% 24.73% | Perf 5Y | -98.41% |
| Dividend TTM | - | EV/Sales | 3.87 | Sales Y/Y TTM | -51.03% | Oper. Margin | -230.91% | ATR (14) | 0.19 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.15 | EPS Q/Q | -42.54% | Profit Margin | -345.76% | RSI (14) | 46.66 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.15 | Sales Q/Q | -77.37% | SMA20 | -19.22% ($1.46) | Beta | 0.74 | Target Price | $6 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | 15.28% ($1.02) | Rel Volume | 0.04 | Prev Close | $1.24 |
| Employees | 115 | LT Debt/Eq | - | EPS/Sales Surpr. | -36% - | SMA200 | 6.41% ($1.11) | Avg Volume(3M) | 3.89M | Price | $1.18 |
| IPO | 2019/8/8 | Option/Short | Yes/Yes | Trades | 990 | Volume | 154,730 | Change | -4.84% |
Company
CELU is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 This regenerative medicine company treats diabetic foot ulcers and tendon injuries using cells and biomaterials extracted from post-birth placentas. Building on revenue from its biobanking (umbilical cord storage) business, the company is working toward commercializing FDA 510(k)-cleared medical devices, including tendon lab products and bone fillers.
Over the past 1 year, roughly in the middle
54% below its 1-year high.
CELU has weak earning power
-230.91% of revenue is kept as operating profit.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -48.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 7.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $34M.
CELU $34M PER -
VRTX $131B PER 30.0
REGN $83B PER 19.9
MRNA $73B PER -
FAQ
What kind of company is CELU?
CELU belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CELU?
The market cap of CELU is approximately $34M, ranking 5,107 within its sector.
What is the 52-week high and low for CELU?
CELU has recorded a 52-week high of $2.55 and a low of $0.56.
